Cowden Syndrome-associated Germline Succinate Dehydrogenase Complex Subunit D (SDHD) Variants Cause PTEN-mediated Down-regulation of Autophagy in Thyroid Cancer Cells
Overview
Molecular Biology
Affiliations
Thyroid cancer is a major component cancer of Cowden syndrome (CS), a disorder typically associated with germline mutations in PTEN. Germline variants in succinate dehydrogenase genes (SDHx) co-occurring with PTEN germline mutations confer a 2-fold increased prevalence (OR 2.7) of thyroid cancer compared to PTEN-associated CS but 50% decreased prevalence (OR 0.54) of thyroid cancer compared to SDHx-associated CS. We have previously shown that CS-associated SDHD variants G12S and H50R induce PTEN oxidation and nuclear accumulation in thyroid cancer. Our current study shows that SDHD-G12S and -H50R variants cause down-regulation of autophagy, demonstrating a role for SDHD in autophagy-associated pathogenesis of differentiated thyroid cancer. These findings could explain the increased prevalence of thyroid cancer in CS patients with SDHx germline mutations compared to those with PTEN mutations alone. Importantly, we demonstrate the dependence of this process on functional wild-type PTEN with reversal of decreased autophagy after PTEN knockdown. The latter could explain the clinically observed decrease in thyroid cancer prevalence in patients with co-existent PTEN mutations and SDHx variants. We also show that SDHD-G12S/H50R promotes mono-ubiquitination of PTEN, causing its translocation into the nucleus, upregulation of AKT and consequent phosphorylation of FOXO3a. Furthermore, SDHD-G12S/H50R-mediated increase in acetylation of FOXO3a further enhances AKT-associated phosphorylation of FOXO3a. This combination of phosphorylation and acetylation of FOXO3a results in its nuclear export for degradation and consequent down-regulation of FOXO3a-target autophagy-related gene (ATG) expression. Overall, our study reveals a novel mechanism of crosstalk amongst SDHD, PTEN and autophagy pathways and their potential roles in thyroid carcinogenesis.
Reprogramming of Thyroid Cancer Metabolism: from Mechanism to Therapeutic Strategy.
Wan Y, Li G, Cui G, Duan S, Chang S Mol Cancer. 2025; 24(1):74.
PMID: 40069775 PMC: 11895238. DOI: 10.1186/s12943-025-02263-4.
Nuclear PTEN's Functions in Suppressing Tumorigenesis: Implications for Rare Cancers.
Langdon C Biomolecules. 2023; 13(2).
PMID: 36830628 PMC: 9953540. DOI: 10.3390/biom13020259.
Looking at Thyroid Cancer from the Tumor-Suppressor Genes Point of View.
Rajabi S, Alix-Panabieres C, Alaei A, Abooshahab R, Shakib H, Ashrafi M Cancers (Basel). 2022; 14(10).
PMID: 35626065 PMC: 9139614. DOI: 10.3390/cancers14102461.
Role of succinylation modification in thyroid cancer and breast cancer.
Mu R, Ma Z, Lu C, Wang H, Cheng X, Tuo B Am J Cancer Res. 2021; 11(10):4683-4699.
PMID: 34765287 PMC: 8569371.
Mitochondrial Tumor Suppressors-The Energetic Enemies of Tumor Progression.
Jakoube P, Cutano V, Gonzalez-Morena J, Keckesova Z Cancer Res. 2021; 81(18):4652-4667.
PMID: 34183354 PMC: 9397617. DOI: 10.1158/0008-5472.CAN-21-0518.